Navigation Links
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
Date:10/21/2011

the company and its product pipeline to investors on a conference call. To participate in the conference call, please call one of the following telephone numbers 15 minutes prior to the event, using access code 6749807: +31(0)20-721-9158 for the Netherlands and +44(0)20-3450-9987 for the UK. Following the presentation, the lines will be opened for questions. A replay of the call will be available following the event.

About Glybera®

AMT has developed Glybera as a treatment for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating and life-threatening clinical complication of LPLD. Glybera® has orphan drug status in the EU and US.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. In addition to Glybera, AMT has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Research and ... Electronics Market by Material, by Application, Geography - Global ... their offering. Organic electronics, also called ... of material science which deals with small conductive molecules ... because small molecules and polymers are carbon based, made ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/19/2014)... -- NextCODE Health, which enables clinicians and researchers to use ... announced the launch of its new genomic data analysis and ... Society of Human Genetics (ASHG) annual meeting in ... apply for free beta access, visit www.nextcode.com . A ... viewed here . The Exchange: ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Sept. 22, 2011 PrimeraDx today announced that Albert Luderer ... President and CEO Matthew McManus commented:  "We are excited ...  We have just launched the ICE Plex System, which ... high multiplex, multi-modal qPCR, and Al brings many years of ...
... A team of researchers from Roche ( SIX: RO, ... and Early Development and Roche NimbleGen, reported inGenome Research (1) ... the cynomolgus monkey ( Macaca fascicularis ) and developed a ... in preclinical drug safety research. The cynomolgus macaque ...
... a rain, the cupped leaf of a pitcher plant becomes ... ants, spiders, and even little frogs. One by one, they ... a group of applied scientists at Harvard have created a ... blood and oil, and does so even under harsh conditions ...
Cached Biology Technology:PrimeraDx Appoints Albert A. Luderer to its Board of Directors 2Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment 2Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment 3Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment 4Slippery slope:Researchers take advice from a carnivorous plant 2Slippery slope:Researchers take advice from a carnivorous plant 3
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... linking prostate cancer to an obscure retrovirus derived from ... a forensic analysis of tissue samples and lab experiments ... confirmed. The connection, which scientists have questioned repeatedly ... than six years ago, when the telltale signature of ...
... wildlife ecologist Aldo Leopold was a meticulous taker of field ... at his Sauk County shack in Depression-era Wisconsin, Leopold routinely ... the first pre-dawn calls of the indigo bunting or robin, ... he heard, when he heard them, and details such as ...
... Md. (September 18, 2012)Propelled by rapid growth in the ... the American Physiological Society (APS; www.the-APS.org ), announced ... its editorial policy. The journal will continue to ... will dramatically increase the scope of papers accepted to ...
Cached Biology News:New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause 2New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause 3New study confirms erroneous link between XMRV and prostate cancer-contamination was the cause 4Aldo Leopold's field notes score a lost 'soundscape' 2Aldo Leopold's field notes score a lost 'soundscape' 3Physiological Genomics journal announces a major restructuring 2Physiological Genomics journal announces a major restructuring 3Physiological Genomics journal announces a major restructuring 4Physiological Genomics journal announces a major restructuring 5
HistoScan AP Universal Goat Kit...
...
Used in May-Grunwald Giemsa stain....
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
Biology Products: